Meeting
2022 ASCO Annual Meeting
Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy.
Authors
Deepak Bhamidipati
The University of Texas MD Anderson Cancer Center, Houston, TX
Deepak Bhamidipati , Kanwal Pratap Singh Raghav , Van K. Morris II, Scott Kopetz , Bryan K. Kee , Benny Johnson , Jason Willis , Arvind Dasari , Maria Pia Morelli , Christine Megerdichian Parseghian , Michael Sangmin Lee , Phat Le , John Paul Y.C. Shen , Kaysia Ludford , Michael J. Overman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Biologic Correlates
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3524)
DOI
10.1200/JCO.2022.40.16_suppl.3524
Abstract #
3524
Poster Bd #
318
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Hematological profile: A prognosis tool in melanoma patients treated with immunotherapy.
First Author: Soraia Lobo Martins
Poster
2019 Genitourinary Cancers Symposium
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for overall survival in men with advanced prostate cancer treated with platinum chemotherapy.
First Author: Panagiotis J. Vlachostergios
Poster
2019 Genitourinary Cancers Symposium
Inflammatory markers at baseline (C1) and cycle 3 (C3) and their association with clinical outcomes in urothelial cancer patients (pts) treated with immunotherapy (IO).
First Author: Julie M. Shabto
Poster
2018 Gastrointestinal Cancers Symposium
The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab.
First Author: Stephen John Clarke